Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.24, issue.26, pp.4293-300, 2006. ,
DOI : 10.1200/JCO.2005.01.3441
The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy, Clinical Cancer Research, vol.13, issue.11, pp.3109-3123, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-2798
Signal Transduction Pathway Targets for Anticancer Drug Discovery, Current Pharmaceutical Design, vol.6, issue.4, pp.361-378, 2000. ,
DOI : 10.2174/1381612003400821
Reversible Posterior Leukoencephalopathy Syndrome After Bevacizumab/FOLFIRI Regimen for Metastatic Colon Cancer, Archives of Neurology, vol.63, issue.10, pp.1475-1483, 2006. ,
DOI : 10.1001/archneur.63.10.1475
Phosphatidylinositol 3-Kinase/Akt Signaling Is Neither Required for Hypoxic Stabilization of HIF-1?? nor Sufficient for HIF-1-dependent Target Gene Transcription, Journal of Biological Chemistry, vol.60, issue.17, pp.15162-70, 2002. ,
DOI : 10.1074/jbc.M100677200
Inhibition of Vascular Endothelial Growth Factor Receptor Signaling in Angiogenic Tumor Vasculature, Adv Genet, vol.67, pp.1-27, 2009. ,
DOI : 10.1016/S0065-2660(09)67001-2
A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed enfothelial network and is regulated by PDGF-b and VEGF, Development, vol.125, pp.1591-98, 1998. ,
Angiogenesis: Tumorigenesis and the angiogenic switch, Nature Reviews Cancer, vol.3, issue.6, pp.401-411, 2002. ,
DOI : 10.1038/nrc1093
Toxicity of sorafenib: clinical and molecular aspects, Expert Opinion on Drug Safety, vol.3, issue.2, pp.275-287, 2010. ,
DOI : 10.1158/1078-0432.CCR-06-0051
Utilisation du soraf??nib (Nexavar??) dans le traitement du carcinome h??patocellulaire??: recommandations Prodige Afef, Gastroent??rologie Clinique et Biologique, vol.32, issue.1, pp.3-7, 2008. ,
DOI : 10.1016/j.gcb.2007.11.001
Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells, Cancer Research, vol.64, issue.1, pp.252-61, 2004. ,
DOI : 10.1158/0008-5472.CAN-3554-2
Pazopanib, Nature Reviews Drug Discovery, vol.372, issue.1, pp.17-25, 2010. ,
DOI : 10.1038/nrd3073
Blood vessels and nerves: common signals, pathways and diseases, Nature Reviews Genetics, vol.107, issue.9, pp.710-730, 2003. ,
DOI : 10.1046/j.1469-7580.2000.19740591.x
Everolimus, Drugs, vol.349, issue.23, pp.861-72, 2004. ,
DOI : 10.2165/00003495-200464080-00005
Sunitinib et??hypothyro??die, Mise au point, pp.332-338, 2007. ,
DOI : 10.1016/j.ando.2007.06.027
Chemotherapy induced reversible posterior leukoencephalopathy syndrome, Lung Cancer, vol.56, issue.3, pp.459-63, 2007. ,
DOI : 10.1016/j.lungcan.2007.01.012
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors, Annals of Internal Medicine, vol.145, issue.9, pp.660-664, 2006. ,
DOI : 10.7326/0003-4819-145-9-200611070-00008
Métabolisme cellulaire : la signalisation de mTOR comme cible liée au métabolisme et à la synthèse des protéines in Le concept de cible en cancérologie, 2008. ,
Everolimus, Drugs, vol.79, issue.2, pp.547-70, 2006. ,
DOI : 10.2165/00003495-200666040-00009
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases, Journal of Clinical Investigation, vol.111, issue.5, pp.707-723, 2003. ,
DOI : 10.1172/JCI17423
Signaling Inhibitors in Metastatic Renal Cell Carcinoma, The Cancer Journal, vol.14, issue.5, pp.325-334, 2008. ,
DOI : 10.1097/PPO.0b013e3181867605
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-159, 2007. ,
DOI : 10.1056/NEJMoa060655
Current development of mTOR inhibitors as anticancer agents, Nature Reviews Drug Discovery, vol.10, issue.Abs. LBA 4, pp.671-88, 2006. ,
DOI : 10.1158/1078-0432.CCR-04-0035
Les facteurs de croissance de l'endothélium vasculaire et leurs récepteurs in L'angiogenèse, 2009. ,
The biology of VEGF and its receptors, Nature Medicine, vol.99, issue.21, pp.669-76, 2003. ,
DOI : 10.1073/pnas.152324099
Sorafenib: delivering a targeted drug to the right targets, Expert Review of Anticancer Therapy, vol.23, issue.5, pp.617-626, 2007. ,
DOI : 10.1200/jco.2005.23.16_suppl.3037
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1., Molecular and Cellular Biology, vol.16, issue.9, pp.4604-4617, 1996. ,
DOI : 10.1128/MCB.16.9.4604
Lapatinib, Drugs, vol.14, issue.1, pp.2125-2148, 2009. ,
DOI : 10.1016/S1359-6349(07)70874-1
Targeting Tumor Angiogenesis, Seminars in Oncology, vol.36, pp.12-19, 2009. ,
DOI : 10.1053/j.seminoncol.2009.02.002
Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006, Journal of Clinical Oncology, vol.24, issue.28, p.48, 2006. ,
DOI : 10.1200/JCO.2006.08.4608
Ciblage pharmacologique des récepteurs du facteur de croissance de l'endothélium vasculaire in L'angiogenèse, 2009. ,
Effets vasculaires et r??naux des m??dicaments anti-angiog??niques??: recommandations fran??aises pour la pratique (SN, SFHTA, APNET, FFCD), N??phrologie & Th??rapeutique, vol.4, issue.7, pp.602-617, 2008. ,
DOI : 10.1016/j.nephro.2008.10.002
The Hallmarks of Cancer, Cell, vol.100, issue.1, pp.57-70, 2000. ,
DOI : 10.1016/S0092-8674(00)81683-9
Rapamycin: Something Old, Something New, Sometimes Borrowed and Now Renewed, Clinical Pharmacology & Therapeutics, vol.431, issue.4, pp.381-389, 2007. ,
DOI : 10.4049/jimmunol.177.2.944
Angiogenesisin the early human chorion and in the primary placenta of the macaque monkey, Contrib Embryol Caregie Inst Washington, vol.25, pp.37-38, 1935. ,
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis, Journal of Clinical Oncology, vol.23, issue.5, pp.1011-1038, 2005. ,
DOI : 10.1200/JCO.2005.06.081
The ErbB receptors and their role in cancer progression, Experimental Cell Research, vol.284, issue.1, pp.99-110, 2033. ,
DOI : 10.1016/S0014-4827(02)00099-X
: Directing Key Signaling Networks Throughout Life, Annual Review of Pharmacology and Toxicology, vol.44, issue.1, pp.195-217, 2004. ,
DOI : 10.1146/annurev.pharmtox.44.101802.121440
Growth factors of the EGF family and their receptors, Bull Cancer, vol.hors série, pp.17-24, 2006. ,
Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) -dependent signaling, The FASEB Journal, vol.16, issue.8, pp.771-80, 2002. ,
DOI : 10.1126/science.2343305
Vascular Endothelial Growth Factor Blockade Promotes the Transition From Compensatory Cardiac Hypertrophy to Failure in Response to Pressure Overload, Hypertension, vol.47, issue.5, pp.887-93, 2006. ,
DOI : 10.1161/01.HYP.0000215207.54689.31
Optimization of cyclosporine therapy, Transplant Proc, vol.25, pp.5-9, 2003. ,
Mechanisms of adverse effects of anti-VEGF therapy for cancer, British Journal of Cancer, vol.280, issue.12 ,
DOI : 10.1038/nm1428
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature, American Journal of Physiology-Heart and Circulatory Physiology, vol.290, issue.2, pp.560-76, 2006. ,
DOI : 10.1016/S0002-9440(10)62567-9
Everolimus, in advanced renal cell carcinoma, Drugs, vol.69, issue.15, pp.2115-2124, 2009. ,
Iressa ® " ), an oral EGFR-TKI (epidermal growth factor tyrosine kinase inhibitor) : pharmacokinetic results of a phase I study in patients with advanced cancer, Proc Am Ass Cancer Res, vol.41, p.612, 2000. ,
Phase I study of oral ZD 1839 Iressa ® " ), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFr- TKI) : evidence of good tolerability and activity, Poster, vol.99, 1999. ,
Systemic Therapy for Metastatic Renal Cell Carcinoma, Urologic Clinics of North America, vol.35, issue.4, pp.687-701, 2008. ,
DOI : 10.1016/j.ucl.2008.07.007
mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor, Clinical Cancer Research, vol.15, issue.5, pp.1612-1634, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2057
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics, Cancer Chemotherapy and Pharmacology, vol.30, issue.5, pp.685-92, 2006. ,
DOI : 10.5414/CPP40580
Microvascular Plasticity and Experimental Heart Failure, Hypertension, vol.47, issue.5, pp.827-836, 2006. ,
DOI : 10.1161/01.HYP.0000215283.53943.39
New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors, Breast Cancer Research, vol.82, issue.Suppl 1, pp.204-214, 2004. ,
DOI : 10.1093/jnci/djg117
Sorafenib in Advanced Hepatocellular Carcinoma, New England Journal of Medicine, vol.359, issue.4, pp.378-90, 2008. ,
DOI : 10.1056/NEJMoa0708857
Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited, Cancer Cell, vol.15, issue.3 ,
DOI : 10.1016/j.ccr.2009.02.007
URL : https://doi.org/10.1016/j.ccr.2009.02.007
Overexpression and Other Tumor Biologic Variables, Journal of Clinical Oncology, vol.19, issue.2, pp.329-364, 2001. ,
DOI : 10.1200/JCO.2001.19.2.329
Les molécules spécifiques des cibles membranaires in Le concept de cible en cancérologie, 2008. ,
Multiple positive and negative regulators of signaling by the EGF-receptor, Current Opinion in Cell Biology, vol.11, issue.2, pp.190-196, 1999. ,
DOI : 10.1016/S0955-0674(99)80025-8
Targeting of membrane receptor tyrosine kinases : is there resistance in the HER?, Bull Cancer, vol.91, issue.9, pp.685-94, 2004. ,
Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions, The Oncologist, vol.11, issue.7, pp.753-64, 2006. ,
DOI : 10.1634/theoncologist.11-7-753
Toxicité cardio-vasculaire des thérapeutiques anti-angiogènes in L'angiogenèse, p.134, 2009. ,
The EGF Receptor Hokey-Cokey, Cancer Cell, vol.11, issue.3, pp.209-220, 2007. ,
DOI : 10.1016/j.ccr.2007.02.021
Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor Subfamily, Drugs, vol.11, issue.4, pp.753-767, 2000. ,
DOI : 10.3109/10428199809057550
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment, Endocrine Related Cancer, vol.10, issue.1, pp.1-21, 2003. ,
DOI : 10.1677/erc.0.0100001
Current methods for the generation of human antibodies for the treatment of autoimmune diseases, Drug Discovery Today, vol.8, issue.18, pp.845-851, 2003. ,
DOI : 10.1016/S1359-6446(03)02803-4
High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor, European Urology, vol.53, issue.2, pp.376-81, 2008. ,
DOI : 10.1016/j.eururo.2007.08.053
and Responsiveness of Breast Cancer to Adjuvant Chemotherapy, New England Journal of Medicine, vol.354, issue.20, pp.2103-2114, 2006. ,
DOI : 10.1056/NEJMoa054504
Development of humanized antibodies as cancer therapeutics, Methods, vol.36, issue.1, pp.84-95, 2005. ,
DOI : 10.1016/j.ymeth.2005.01.008
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.24, issue.16, pp.2505-2517, 2006. ,
DOI : 10.1200/JCO.2005.03.6723
Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy, Drugs, vol.3, issue.2-3, pp.15-23, 2000. ,
DOI : 10.2165/00003495-200060001-00002
Phosphatidylinositol-3-OH kinase direct target of Ras, Nature, vol.370, issue.6490, pp.527-559, 1994. ,
DOI : 10.1038/370527a0
Signal Events: Cell Signal Transduction and Its Inhibition in Cancer, The Oncologist, vol.8, issue.90003, pp.5-17, 2003. ,
DOI : 10.1634/theoncologist.8-suppl_3-5
Targeting signal transduction, the erbB receptor family as a target for therapeutic development. Horizons in Cancer Therapeutics : From Bench to, Bedside, vol.2, issue.2, pp.3-35, 2001. ,
Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results, Journal of Clinical Oncology, vol.23, issue.24, pp.5474-83, 2005. ,
DOI : 10.1200/JCO.2005.04.192
The effects of the novel, reversible epidermal growth factor receptor / ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro andin vivo, Mol Cancer Ther, vol.1, pp.85-94, 2001. ,
Enhanced radiation damage of tumor vasculature by mTOR inhibitors, Oncogene, vol.24, issue.35, pp.5414-5436, 2005. ,
DOI : 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.0.CO;2-S
Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure, Journal of Clinical Investigation, vol.115, issue.8, pp.2108-2126, 2005. ,
DOI : 10.1172/JCI24682
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.28, issue.6, pp.1061-1069, 2010. ,
DOI : 10.1200/JCO.2009.23.9764
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib, Annals of Oncology, vol.19, issue.2, pp.265-273, 2008. ,
DOI : 10.1093/annonc/mdm483
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy, Nature Reviews Clinical Oncology, vol.18, issue.4, pp.219-247, 2009. ,
DOI : 10.7326/0003-4819-145-9-200611070-00015
Structure, function and transforming potential of the epidermal growth factor receptor, Molecular and Cellular Endocrinology, vol.70, issue.3, pp.205-216, 1990. ,
DOI : 10.1016/0303-7207(90)90211-P
Rapamucin (AY-22, 989), a new antifungal antibiotic. I ,
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF, Cell, vol.116, issue.6, pp.855-67, 2004. ,
DOI : 10.1016/S0092-8674(04)00215-6
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis, Cancer Research, vol.64, issue.19, pp.7099-109, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-1443
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer, Nature Medicine, vol.15, issue.2, pp.145-192, 2004. ,
DOI : 10.1007/BF00437479
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways, Oncogene, vol.21, issue.41, pp.6255-6263, 2002. ,
DOI : 10.1038/sj.onc.1202319
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy, British Journal of Dermatology, vol.24, issue.3, pp.592-598, 2008. ,
DOI : 10.1111/j.1365-2133.2007.08357.x
Inhibiteurs de tyrosine kinase utilisés dans les tumeurs solides: proposition de fiches d'utilisation pratique destin ées à l'équipe officinale Jury: Président : Monsieur le Professeur MERLIN Directeur: Madame Béatrice DEMORE Juges ,
('l\(~ 2.P \ Doyen de la Faculté de Pharmacie de l ,